Impact of pneumococcal conjugate vaccine in children morbidity and mortality in Peru: Time series analyses

Vaccine

Volumn 34, Issue 39, 2016, Pages 4738-4743

  Suarez, Victor ^a   Michel, Fabiana ^b   Toscano, Cristiana M ^c   Bierrenbach, Ana Luiza ^d   Gonzales, Marco ^e   Alencar, Airlane Pereira ^f   Ruiz Matus, Cuauhtemoc ^g   Andrus, Jon K ^h   de Oliveira, Lucia H ^g  

^a INSTITUTO NACIONAL DE SALUD   (Peru)

^b PAN AMERICAN HEALTH ORGANIZATION   (Peru)

^c FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^d Sanas Epidemiology and Research   (Brazil)

^e Independent Consultant   (United States)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

^g PAN AMERICAN HEALTH ORGANIZATION   (United States)

^h SABIN VACCINE INSTITUTE   (United States)

Author keywords

Immunization programs; Impact; Pneumococcal conjugate vaccines; Pneumococcal diseases; Time series

Indexed keywords

PNEUMOCOCCUS VACCINE; 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE;

ACUTE OTITIS MEDIA; ACUTE RESPIRATORY TRACT DISEASE; AGE DISTRIBUTION; ARTICLE; CHILD; CHILD HOSPITALIZATION; CHILDHOOD MORTALITY; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; HEALTH CARE UTILIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY RATE; OUTPATIENT CARE; PERUVIAN; PRIORITY JOURNAL; SEX RATIO; TIME SERIES ANALYSIS; EPIDEMIOLOGY; HOSPITALIZATION; MORTALITY; OTITIS MEDIA; PERU; PNEUMOCOCCAL INFECTION; PNEUMONIA; PREVENTIVE HEALTH SERVICE; STATISTICS AND NUMERICAL DATA;

HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HOSPITALIZATION; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INTERRUPTED TIME SERIES ANALYSIS; MORBIDITY; OTITIS MEDIA; PERU; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA;

EID: 84991598806     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.07.027     Document Type: Article

References (31)

1. [1] O'Brien, K.L., Wolfson, L.J., Watt, J.P., Henkle, E., Deloria-Knoll, M., McCall, N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374 (2009), 893–902.
2. [2] Constenla, D., Gomez, E., Pio de la Hoz, F., O'Loughlin, R., Sinha, A., Valencia, J.E., et al. The burden of pneumococcal disease and cost-effectiveness of a pneumococcal vaccine in Latin America and the Caribbean. 2007, institute S, Washington, DC.
3. [3] US Federal Drug Administration. FDA. Vaccines, blood & biologics. February 17, 2000. Approval Letter. FDA; 2000.
4. [4] World Health Organization. WHO. Immunization standard. WHO prequalified vaccines. Geneva, Switzerland: WHO.
5. [5] Pneumococcal conjugate vaccine for childhood immunization–WHO position paper. Wkly Epidemiol Rec. 2007;82:93–104.
6. [6] Progress in introduction of pneumococcal conjugate vaccine–worldwide, 2000–2008. MMWR Morb Mortal Wkly Rep. 2008;57:1148–51.
7. [7] De Wals, P., Robin, E., Fortin, E., Thibeault, R., Ouakki, M., Douville-Fradet, M., Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J 27 (2008), 963–968.
8. [8] Griffin, M.R., Zhu, Y., Moore, M.R., Whitney, C.G., Grijalva, C.G., U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 369 (2013), 155–163.
9. [9] Grijalva, C.G., Griffin, M.R., Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA. Expert Rev Vaccines 7 (2008), 83–95.
10. [10] Jardine, A., Menzies, R.I., McIntyre, P.B., Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J 29 (2010), 607–612.
11. [11] Koshy, E., Murray, J., Bottle, A., Sharland, M., Saxena, S., Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997–2008. Thorax 65 (2010), 770–774.
12. [12] Simonsen, L., Taylor, R.J., Young-Xu, Y., Haber, M., May, L., Klugman, K.P., Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio 2 (2011), e00309–e00310.
13. [13] Afonso, E.T., Minamisava, R., Bierrenbach, A.L., Escalante, J.J., Alencar, A.P., Domingues, C.M., et al. Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerg Infect Dis 19 (2013), 589–597.
14. [14] Scotta, M.C., Veras, T.N., Klein, P.C., Tronco, V., Polack, F.P., Mattiello, R., et al. Impact of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on childhood pneumonia hospitalizations in Brazil two years after introduction. Vaccine 32 (2014), 4495–4499.
15. [15] PRAES, La carga de enfermedad y lesiones en el Peru Lima: PRAES. 2008, USAID-Peru.
16. [16] Ochoa, T.J., Egoavil, M., Castillo, M.E., Reyes, I., Chaparro, E., Silva, W., et al. Invasive pneumococcal diseases among hospitalized children in Lima, Peru. Rev Panam Salud Publ 28 (2010), 121–127.
17. [17] Verne Martin, C., Ugarte Taboada, C., Inmunización conceptos generales esquemas y el futuro. Rev peru pediatr 61 (2008), 36–43.
18. [18] Pan American Health Organization (PAHO), Health in the Americas. 2007, PAHO, Washington, DC.
19. [19] Pan American Health Organization (PAHO), Health situation in the Americas: basic indicators 2013. 2014, PAHO, Washington.
20. [20] Peru. Ministerio de Salud. Estadisticas vitales. In: Oficina General de Estadistica e Informática. Editor: Ministerio de Salud.
21. [21] Peru. Ministerio de Salud. Coberturas vacunales. In: Estrategia Sanitaria Nacional de Inmunizaciones. Editor: Ministerio de Salud.
22. [22] Peru. Ministerio de Salud. Estudio de costo efectividad de las vacunas deca- y trece-valente para la prevención de enfermedad asociada a Streptococcus pneumoniae en niños menores de 5 años en Perú. Nota Técnica 2012; N.3.
23. [23] Cullotta, A.R., Kalter, H.D., Delgado, J., Gilman, R.H., Facklam, R.R., Velapatino, B., et al. Antimicrobial susceptibilities and serotype distribution of Streptococcus pneumoniae isolates from a low socioeconomic area in Lima, Peru. Clin Diagn Lab Immunol 9 (2002), 1328–1331.
24. [24] Mercado, E.H., Egoavil, M., Horna, S.G., Torres, N., Velasquez, R., Castillo, M.E., et al. Pneumococcal serotypes in carrier children prior to the introduction of anti-pneumococcal vaccines in Peru. Rev Peru Med Exp Salud Publ 29 (2012), 53–60.
25. [25] Ochoa, T.J., Rupa, R., Guerra, H., Hernandez, H., Chaparro, E., Tamariz, J., et al. Penicillin resistance and serotypes/serogroups of Streptococcus pneumoniae in nasopharyngeal carrier children younger than 2 years in Lima, Peru. Diagn Microbiol Infect Dis 52 (2005), 59–64.
26. [26] Orellano, E.V., Luna, N.T., Quintana, G.H., Kelly, J.P., Díaz, M.E.C., Diaz, R.H., et al. Antibiotic susceptibility of Streptococcus pneumoniae in nasopharyngeal carriers in healthy children younger than one year of age in Lima, Perú. Acta Med Per, 25, 2008, 5.
27. [27] Grupo Multifuncional de Neumonias, Vigilancia epidemiologica centinela de Haemophilus influenzae y Streptococcus pneumonia en menores de 5 años en el Peru. Rev Peru Med Exp Salud Publ, 20, 2003, 5.
28. [28] Ygreda, J.P., Pérez, F.L., Galarza, R.R., Da Fieno, J.T., Moreno, V.S., Sánchez, C.C., et al. Etiology of community acquired pneumonia in children 2–59 months old in two ecologically different communities from Peru. Arch Argen Pediatr, 108, 2010, 8.
29. [29] Rotavirus vaccines. Wkly Epidemiol Rec. 2007;82:285–95.
30. [30] de Oliveira, L.H., Toscano, C.M., Sanwogou, N.J., Ruiz-Matus, C., Tambini, G., Roses-Periago, M., et al. Systematic documentation of new vaccine introduction in selected countries of the Latin American Region. Vaccine 31 Suppl 3 (2013), C114–C122.
31. [31] Sgambatti, S., Minamisava, R., Afonso, E.T., Toscano, C.M., Bierrenbach, A.L., Andrade, A.L., Appropriateness of administrative data for vaccine impact evaluation: the case of pneumonia hospitalizations and pneumococcal vaccine in Brazil. Epidemiol Infect 143 (2015), 334–342.